Amgen Responds to 'Flawed' Cholesterol Study
In a letter to BioPharma Dive, Amgen has refuted the ‘flawed analysis’ that attacked the value of PCSK9 cholesterol drugs.
The study, published in JAMA, claimed that PCSK9 inhibitors were not as cost effective as other treatment options; in this letter, Amgen counter-claims that the study has exaggerated the costs of PCSK9 inhibitors.
Amgen states that the study “could have consequences for patients” by making it more difficult for patients to access PCSK9s.
The study, published in JAMA, claimed that PCSK9 inhibitors were not as cost effective as other treatment options; in this letter, Amgen counter-claims that the study has exaggerated the costs of PCSK9 inhibitors.
Amgen states that the study “could have consequences for patients” by making it more difficult for patients to access PCSK9s.